|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12...89101112131415161718...156157» |
- || Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: Clinical Disease Activity With Long Term Natalizumab Treatment (clinicaltrials.gov) - Oct 4, 2017
P=N/A, N=277, Active, not recruiting, Sponsor: Biogen
Trial primary completion date: Jun 2017 --> Dec 2017
- | Firdapse (amifampridine) / BioMarin, Catalyst Pharma
Trial primary completion date: Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) (clinicaltrials.gov) - Oct 4, 2017
P3, N=28, Recruiting, Sponsor: Catalyst Pharmaceuticals, Inc.
Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Jul 2017 --> Oct 2017
- |||| lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
Trial completion: Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate (clinicaltrials.gov) - Oct 4, 2017
P2, N=83, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Jul 2017 --> Oct 2017 Active, not recruiting --> Completed
- || Litfulo (ritlecitinib) / Pfizer
Trial primary completion date: Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate (clinicaltrials.gov) - Oct 4, 2017
P2a, N=60, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial primary completion date: Mar 2018 --> Dec 2017
- | Trial completion: Spine QCT: Spine Quantitative Computed Tomography (QCT) (clinicaltrials.gov) - Oct 4, 2017
P=N/A, N=127, Completed, Sponsor: Children's Hospital of Philadelphia
Trial primary completion date: Mar 2018 --> Dec 2017 Active, not recruiting --> Completed
- | Trial completion: Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children (clinicaltrials.gov) - Oct 3, 2017
P=N/A, N=32, Completed, Sponsor: Children's Hospital of Philadelphia
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | hydroxychloroquine / Generic mfg.
Trial completion, Enrollment change, Trial initiation date: Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 3, 2017
P=N/A, N=37, Completed, Sponsor: Indonesia University
Active, not recruiting --> Completed Recruiting --> Completed | N=77 --> 37 | Initiation date: May 2017 --> Jan 2017
- | Enrollment open: MSCopilot: Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients (clinicaltrials.gov) - Oct 3, 2017
P=N/A, N=222, Recruiting, Sponsor: Ad scientiam
Recruiting --> Completed | N=77 --> 37 | Initiation date: May 2017 --> Jan 2017 Not yet recruiting --> Recruiting
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion, Adherence: Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction (clinicaltrials.gov) - Oct 2, 2017
P=N/A, N=146, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial completion, Enrollment change: DEPICT 1: Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (clinicaltrials.gov) - Oct 2, 2017
P3, N=833, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=1626 --> 833
- | JNJ-55920839 / J&J
Trial suspension: A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 2, 2017
P1, N=80, Suspended, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | N=1626 --> 833 Recruiting --> Suspended
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct) (clinicaltrials.gov) - Sep 29, 2017
P=N/A, N=215, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Suspended Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Jun 2017
- | Enrollment closed: Impact of a Nutritional Intervention on Type1 Diabetes Adult With Metabolic Syndrome (clinicaltrials.gov) - Sep 28, 2017
P=N/A, N=29, Active, not recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Jun 2017 Recruiting --> Active, not recruiting
- || Trial primary completion date: BIOFLOW-III Israel Satellite Registry (clinicaltrials.gov) - Sep 28, 2017
P=N/A, N=120, Completed, Sponsor: BIOTRONIK Israel
Recruiting --> Active, not recruiting Trial primary completion date: May 2014 --> Jun 2015
- ||| Trial completion: BIOFLOW III Asia Registry Orsiro Stent System (clinicaltrials.gov) - Sep 28, 2017
P=N/A, N=387, Completed, Sponsor: BIOTRONIK Asia Pacific Pte Ltd
Trial primary completion date: May 2014 --> Jun 2015 Active, not recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: Effect of Fingolimod on Neurodegeneration (clinicaltrials.gov) - Sep 28, 2017
P4, N=4, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=120 --> 4 | Recruiting --> Terminated | Trial primary completion date: Oct 2018 --> Jan 2017; The trial was terminated due to low enrollment.
- | prednisone / Generic mfg., azathioprine / Generic mfg.
Trial completion, Trial primary completion date: MYACOR: Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis (clinicaltrials.gov) - Sep 27, 2017
P4, N=118, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=120 --> 4 | Recruiting --> Terminated | Trial primary completion date: Oct 2018 --> Jan 2017; The trial was terminated due to low enrollment. Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jul 2017
- | Enrollment change, Trial primary completion date, HEOR, Cost of care: Cost of Care for Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Sep 27, 2017
P=N/A, N=165, Completed, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jul 2017 N=300 --> 165 | Trial primary completion date: Dec 2013 --> Dec 2014
- | dronabinol oral / Generic mfg.
Trial initiation date, Trial primary completion date: Cannabis for Spasticity in Multiple Sclerosis (clinicaltrials.gov) - Sep 26, 2017
P1/2, N=42, Terminated, Sponsor: University of California, Davis
N=300 --> 165 | Trial primary completion date: Dec 2013 --> Dec 2014 Initiation date: Mar 2003 --> Nov 2003 | Trial primary completion date: Jul 2017 --> Feb 2015
- | Phase classification: Yoga for Rheumatoid Arthritis (clinicaltrials.gov) - Sep 26, 2017
P=N/A, N=75, Completed, Sponsor: Johns Hopkins University
Initiation date: Mar 2003 --> Nov 2003 | Trial primary completion date: Jul 2017 --> Feb 2015 Phase classification: P1 --> P=N/A
- | Trial completion: The NOR-SWITCH Study (clinicaltrials.gov) - Sep 25, 2017
P4, N=482, Completed, Sponsor: Diakonhjemmet Hospital
Phase classification: P1 --> P=N/A Active, not recruiting --> Completed
- | Trial primary completion date: FMD-ABRA: Full Mouth Disinfection and Antibiotics for Periodontitis in High or Moderate Disease Activity Rheumatoid Arthritis (clinicaltrials.gov) - Sep 21, 2017
P=N/A, N=8, Active, not recruiting, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed Trial primary completion date: Jul 2017 --> Nov 2017
- | Trial completion: Social Determinants in Chronic Disease in British Columbia (clinicaltrials.gov) - Sep 21, 2017
P=N/A, N=300, Completed, Sponsor: University of British Columbia
Trial primary completion date: Jul 2017 --> Nov 2017 Recruiting --> Completed
- | Trial primary completion date: SAMSPAP: Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial (clinicaltrials.gov) - Sep 20, 2017
P=N/A, N=65, Recruiting, Sponsor: McGill University
Recruiting --> Completed Trial primary completion date: Apr 2017 --> Dec 2017
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Phase classification: Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases (clinicaltrials.gov) - Sep 20, 2017
P4, N=19, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Apr 2017 --> Dec 2017 Phase classification: P=N/A --> P4
- | Trial completion, Enrollment change: RAHExercise: Hand Exercises for Women With Rheumatoid Arthritis and Impaired ADL Ability: an Exploratory Trial (clinicaltrials.gov) - Sep 20, 2017
P=N/A, N=55, Completed, Sponsor: Parker Research Institute
Phase classification: P=N/A --> P4 Recruiting --> Completed | N=90 --> 55
- | Trial primary completion date: Pre-POINT-Early Study (clinicaltrials.gov) - Sep 20, 2017
P2, N=44, Active, not recruiting, Sponsor: Technische Universit
Recruiting --> Completed | N=90 --> 55 Trial primary completion date: Aug 2017 --> Dec 2017
- ||||||| blisibimod (A-623) / Anthera Pharma
Trial completion: BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration (clinicaltrials.gov) - Sep 18, 2017
P2/3, N=57, Completed, Sponsor: Anthera Pharmaceuticals
Trial primary completion date: Aug 2017 --> Dec 2017 Active, not recruiting --> Completed
- | dexamethasone / Generic mfg.
Trial completion, Enrollment change: Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone (clinicaltrials.gov) - Sep 18, 2017
P2/3, N=36, Completed, Sponsor: Isfahan University of Medical Sciences
Active, not recruiting --> Completed Recruiting --> Completed | N=20 --> 36
- | Trial primary completion date, Pneumococcal vaccines: Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar® (clinicaltrials.gov) - Sep 15, 2017
P4, N=500, Enrolling by invitation, Sponsor: Region Skane
Recruiting --> Completed | N=20 --> 36 Trial primary completion date: Dec 2013 --> Dec 2018
- | Biomarker, Trial primary completion date: A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action (clinicaltrials.gov) - Sep 15, 2017
P4, N=200, Recruiting, Sponsor: Medical University of Vienna
Trial primary completion date: Dec 2013 --> Dec 2018 Trial primary completion date: Jul 2017 --> Dec 2017
- | Phase classification, Enrollment change: A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis (clinicaltrials.gov) - Sep 15, 2017
P=N/A, N=218, Active, not recruiting, Sponsor: VA Office of Research and Development
Trial primary completion date: Jul 2017 --> Dec 2017 Phase classification: P3 --> P=N/A | N=600 --> 218
- teriflunomide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis. (clinicaltrials.gov) - Sep 15, 2017
P=N/A, N=26, Terminated, Sponsor: University of North Carolina, Chapel Hill
Phase classification: P3 --> P=N/A | N=600 --> 218 N=46 --> 26 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Dec 2016
- daxdilimab (HZN-7734) / Horizon Therapeutics
Enrollment closed: A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases (clinicaltrials.gov) - Sep 15, 2017
P1, N=36, Active, not recruiting, Sponsor: MedImmune LLC
N=46 --> 26 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Dec 2016 Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Trial initiation date: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan (clinicaltrials.gov) - Sep 14, 2017
P2, N=80, Active, not recruiting, Sponsor: Niigata University Medical & Dental Hospital
Recruiting --> Active, not recruiting Initiation date: May 2016 --> Sep 2016
- |||| Plivensia (sirukumab) / J&J
Trial primary completion date, Monotherapy: SIRROUND-H: A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA (clinicaltrials.gov) - Sep 14, 2017
P3, N=559, Completed, Sponsor: Janssen Research & Development, LLC
Initiation date: May 2016 --> Sep 2016 Trial primary completion date: Oct 2015 --> Aug 2016
- | Trial completion: Insulin-based Strategies to Prevent Hypoglycemia During Exercise (clinicaltrials.gov) - Sep 13, 2017
P=N/A, N=22, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
Trial primary completion date: Oct 2015 --> Aug 2016 Recruiting --> Completed
- | Enrollment change, Trial primary completion date: Anti-nucleosome B Lymphocytes in Lupus (clinicaltrials.gov) - Sep 11, 2017
P=N/A, N=4, Terminated, Sponsor: University Hospital, Strasbourg, France
Recruiting --> Completed N=90 --> 4 | Trial primary completion date: Jul 2016 --> Jul 2015
- || Trial primary completion date: APRAN: Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA. (clinicaltrials.gov) - Sep 11, 2017
P=N/A, N=100, Recruiting, Sponsor: Isabelle Fortin
N=90 --> 4 | Trial primary completion date: Jul 2016 --> Jul 2015 Trial primary completion date: Mar 2017 --> Mar 2018
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date, Trial primary completion date, Combination therapy: Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate (clinicaltrials.gov) - Sep 8, 2017
P=N/A, N=60, Not yet recruiting, Sponsor: AbbVie
Trial primary completion date: Mar 2017 --> Mar 2018 Initiation date: Jun 2017 --> Oct 2017 | Trial primary completion date: Jan 2019 --> Oct 2019
- | Enrollment closed, Phase classification: Insight Kids: Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Sep 8, 2017
P4, N=43, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jun 2017 --> Oct 2017 | Trial primary completion date: Jan 2019 --> Oct 2019 Recruiting --> Active, not recruiting | Phase classification: PN/A --> P4
- Enrollment change, Trial withdrawal: Excia T Cementless EBRA Study (clinicaltrials.gov) - Sep 7, 2017
P=N/A, N=0, Withdrawn, Sponsor: Aesculap AG
Recruiting --> Active, not recruiting | Phase classification: PN/A --> P4 N=100 --> 0 | Not yet recruiting --> Withdrawn
- ||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion, Review, Trial primary completion date: Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis (clinicaltrials.gov) - Sep 6, 2017
P=N/A, N=370, Completed, Sponsor: Janssen Biotech, Inc.
N=100 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2016
- || Betaseron (IFN-β-1b) / Bayer
Enrollment closed, Adherence: Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction (clinicaltrials.gov) - Sep 6, 2017
P=N/A, N=146, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2016 Recruiting --> Active, not recruiting
- Phase classification, Enrollment change, Trial withdrawal, Stroma: Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis (clinicaltrials.gov) - Sep 1, 2017
P=N/A, N=0, Withdrawn, Sponsor: Ageless Regenerative Institute
Recruiting --> Active, not recruiting Phase classification: P1/2 --> P=N/A | N=50 --> 0 | Recruiting --> Withdrawn
- | Phase classification: Overnight Closed Loop Study in U.S. (clinicaltrials.gov) - Sep 1, 2017
P=N/A, N=78, Completed, Sponsor: Medtronic Diabetes
Phase classification: P1/2 --> P=N/A | N=50 --> 0 | Recruiting --> Withdrawn Phase classification: P2 --> P=N/A
- || Enrollment change, Trial primary completion date: International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol (clinicaltrials.gov) - Sep 1, 2017
P=N/A, N=100, Recruiting, Sponsor: University of Virginia
Phase classification: P2 --> P=N/A N=20 --> 100 | Trial primary completion date: Feb 2017 --> Oct 2017
- ||| branebrutinib (BMS-986195) / BMS
Trial completion, Enrollment change: Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects (clinicaltrials.gov) - Aug 31, 2017
P1, N=439, Completed, Sponsor: Bristol-Myers Squibb
N=20 --> 100 | Trial primary completion date: Feb 2017 --> Oct 2017 Active, not recruiting --> Completed | N=118 --> 439
- | Trial completion: Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis (clinicaltrials.gov) - Aug 30, 2017
P=N/A, N=267, Completed, Sponsor: Mount Sinai Rehabilitation Hospital
Active, not recruiting --> Completed | N=118 --> 439 Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: valid-PVLT: Paris Visual Learning Test: a New French Task for Assess Visual Learning and Memory to Multiple Sclerosis Patients (clinicaltrials.gov) - Aug 30, 2017
P=N/A, N=50, Completed, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2017